Here are Thursday’s biggest analyst calls: Nvidia, Dell, Chewy, Verizon, DoorDash, Carvana, Palantir & more

Wall Street rolled out a wave of fresh ratings, target updates, and sector calls on Thursday, spanning semiconductors, AI, e-commerce, banking, and biotech. Here are the highlights investors are watching.

Oppenheimer reiterates Nvidia (NVDA) as Outperform

Oppenheimer remains bullish ahead of next week’s results, citing multiple long-term tailwinds across high-performance gaming, data center/AI, and autonomous driving that support sustained above-trend revenue growth.

Barclays upgrades CIBC (CM) to Overweight from Underweight

Barclays sees further upside for the Canadian bank as it continues progressing toward medium-term goals, pointing to expanding ROE, steadier earnings, positive operating leverage, resilient credit quality, and increased capital returns via buybacks.

Goldman Sachs initiates Credo Technology (CRDO) at Buy

Goldman started coverage with a favorable risk/reward view and a 12-month price target of $165, highlighting the company’s positioning in connectivity solutions.

Evercore ISI adds a tactical Outperform on Dell (DELL), trims target to $160 from $180

Evercore is constructive into earnings, expecting upside to current revenue/EPS estimates ($31.4B/$3.52) on strong near-term demand for traditional hardware and AI compute. The firm also sees a pull-in of PC and server orders as customers move to get ahead of potential memory-driven price increases.

Raymond James upgrades Chewy (CHWY) to Outperform from Market Perform

Following recent share weakness, Raymond James views the setup as compelling, noting an attractive risk/reward near ~8x 2027E EV/EBITDA. The firm sees a low bar and room for top-line and margin improvement through 2026.

Mizuho initiates Tempus AI (TEM) at Outperform

Mizuho began coverage with an Outperform rating and a $100 price target, pointing to significant runway for the AI-driven healthcare company.

RBC initiates Rhythm Pharmaceuticals (RYTM) at Outperform

RBC expects the company to capitalize on momentum in rare obesity, arguing Rhythm is well positioned for growth as it advances its pipeline and commercialization strategy.

Mizuho upgrades LeonaBio to Outperform from Neutral

Mizuho sees a compelling long-term setup with meaningful data expected in 2027, framing the risk/reward as attractive for investors with a multi-year horizon.

KeyBanc raises Symbotic (SYM) to Overweight from Sector Weight

After investor meetings with the CFO and VP of Investor Relations, KeyBanc turned more constructive on SYM’s automation opportunity and set a $70 price target.

Bank of America removes Palantir (PLTR) from the US 1 list, maintains Buy

Palantir was taken off BofA’s top ideas list but retains a Buy rating, signaling continued confidence despite the change in list placement.

Bank of America reiterates Carvana (CVNA) as Buy, trims target to $400 from $460

While reducing its price target following results, BofA says Carvana remains in growth mode with leading e-commerce momentum, driven by geographic expansion and deeper penetration in existing markets.

Wells Fargo initiates AxoGen (AXGN) at Overweight

Wells highlights AxoGen’s differentiated Avance nerve repair platform and the sizable multi-billion-dollar total addressable market in peripheral nerve repair as key drivers of its bullish view.

Needham upgrades Analog Devices (ADI) to Buy from Hold

Needham cites strong F1Q26 results and F2Q26 guidance well above expectations. With operating trends improving, the firm now sees additional upside and moves off the sidelines.

Bank of America upgrades Dentsply Sirona (XRAY) to Buy from Neutral

BofA argues the risk/reward has turned positive at current levels. The firm points to potential catalysts around next week’s 2026 outlook as a possible clearing event for the stock.

Deutsche Bank reiterates DoorDash (DASH) as Buy

Deutsche called the latest earnings a “clearing event,” noting improving unit economics in grocery and retail and positive international contribution profit expected in the second half. The firm anticipates a stronger margin trajectory through 2026 even as growth investments scale.

Daiwa upgrades Verizon (VZ) to Buy from Outperform and T-Mobile (TMUS) to Outperform from Neutral

Daiwa sees the best risk/reward at Verizon given its low valuation. The firm also points to recent price increases on legacy plans across the industry as evidence of growing price rationality, supporting a more constructive stance on both carriers.

Bottom line: Thursday’s updates reinforce ongoing enthusiasm for AI infrastructure and automation, selective optimism in healthcare and biotech pipelines, and improving setup across e-commerce and telecom as pricing discipline and operational efficiencies take hold.